Genotype-Informed Versus Empiric Management of VirEmia

NACompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

March 15, 2023

Study Completion Date

July 8, 2023

Conditions
HIV-1-infection
Interventions
OTHER

Clinical management informed by HIV-1 genotypic resistance testing

"The study intervention will consist of the following components:~1. Genotypic resistance testing (GRT);~2. Review of GRT results by an expert committee providing a treatment recommendation;~3. GRT-based decision on further therapy (switch or maintain current ART regimen; choice of regimen); and~4. GRT-informed adherence support."

Trial Locations (10)

Unknown

Seboche Mission Hospital, Seboche

Baylor Clinic Leribe, Hlotse

Baylor Clinic Butha-Buthe, Butha-Buthe

Baylor Clinic Maseru, Maseru

Baylor Clinic Mohale's Hoek, Mohale's Hoek

Baylor Clinic Mokhotlong, Mokhotlong

One-Stop Clinic and Chronic Diseases Clinic (CDCI) at St Francis Referral Hospital, Ifakara

Mbagala Rangi Tatu Hospital, Dar es Salaam

Temeke Regional Referral Hospital, Dar es Salaam

Upendano Dispensary, Dar es Salaam

All Listed Sponsors
collaborator

University Hospital, Basel, Switzerland

OTHER

collaborator

University of Basel

OTHER

collaborator

SolidarMed, Partnerships for Health

UNKNOWN

collaborator

Seboche Mission Hospital

UNKNOWN

collaborator

Ifakara Health Institute

OTHER

collaborator

Baylor College of Medicine Children's Foundation

UNKNOWN

lead

Swiss Tropical & Public Health Institute

OTHER

NCT04233242 - Genotype-Informed Versus Empiric Management of VirEmia | Biotech Hunter | Biotech Hunter